Table 1.
Baseline characteristics compared between the treatment side and placebo side (split-face study) during the maintenance phase (N = 50).
| Variables | Mean ± SD or N (%) | p value | |
|---|---|---|---|
| Treatment side | Placebo side | ||
| Clinical characteristics | |||
| Acne lesion counts | |||
| Noninflammatory | 8.4 ± 5.8 | 8.7 ± 5.5 | 0.684 |
| Inflammatory | 2.1 ± 1.9 | 1.7 ± 1.3 | 0.060 |
| Total | 10.5 ± 6.5 | 10.3 ± 5.9 | 0.766 |
| IGA scale for acne vulgaris | |||
| Grade 1 (almost clear) | 19 (38%) | 26 (52%) | 0.147 |
| Grade 2 (mild severity) | 24 (48%) | 18 (36%) | |
| Grade 3 (moderate severity) | 7 (14%) | 6 (12%) | |
| Skin bioengineering measurements | |||
| Corneometer (corneometer unit) | 70.4 ± 13.0 | 69.6 ± 12.9 | 0.164 |
| Tewameter (g/h/m2) | 13.2 ± 6.8 | 13.9 ± 8.5 | 0.463 |
| Sebumeter (μg/cm2) | 41.2 ± 24.4 | 40.4 ± 25.9 | 0.603 |
A p value < 0.05 indicates statistical significance. SD: standard deviation; IGA: Investigator's Global Assessment.